Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

10.1056/NEJMoa040938

10.1126/science.1099314

10.1073/pnas.0405220101

10.1056/NEJMoa0810699

10.1056/NEJMoa0904554

10.1056/NEJMoa044238

10.1371/journal.pmed.0020073

10.1126/science.1141478

10.1073/pnas.0710370104

10.3727/096504005775082020

10.1097/MAJ.0b013e31803b8acb

10.1093/jnci/92.3.205

10.1002/emmm.201000070

10.1016/j.ccr.2009.11.022

10.1172/JCI28656

Guix M., Faber A. C., Wang S. E., Olivares M. G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C. L., Engelman J. A., Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609–2619 (2008).

10.1038/onc.2009.526

10.1158/0008-5472.CAN-05-1058

10.1158/1535-7163.MCT-07-0138

10.1158/0008-5472.CAN-07-2460

10.1158/1541-7786.MCR-06-0095

10.1016/j.lungcan.2008.05.017

10.1200/JCO.2009.24.7049

10.1200/JCO.2007.14.8494

10.1016/S1470-2045(09)70364-X

10.1056/NEJMoa0909530

10.1158/0008-5472.CAN-06-3020

10.1038/sj.bjc.6602559

10.1158/1078-0432.CCR-09-1204

10.1158/1078-0432.CCR-09-1001

10.1158/0008-5472.CAN-08-1643

10.1073/pnas.0409773102

10.1126/science.1101637

10.1158/0008-5472.CAN-04-1905

10.1093/jnci/dji238

Amann J., Kalyankrishna S., Massion P. P., Ohm J. E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., Kim Y. H., Pollack J. R., Yanagisawa K., Gazdar A., Minna J. D., Kurie J. M., Carbone D. P., Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65, 226–235 (2005).

10.1126/science.1073096

10.1158/1078-0432.CCR-07-2248

10.1158/1078-0432.CCR-06-0714

10.1158/1078-0432.CCR-06-1570

Mok T., Spigel D. R., Park K., Socinski M. A., Tung S. Y., Kim D., Borzillo G., Zhang H., O’Connell J. P., Jänne P. A., Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28, abstract 7537 (2010).

10.1200/JCO.2009.27.9414

10.1200/jco.2009.27.15_suppl.8063

10.1073/pnas.0905056106

10.1038/nature08622

Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., Koutcher J. A., Spassova M., Ouerfelli O., Mellinghoff I. K., Zakowski M. F., Politi K. A., Pao W., Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000–3010 (2009).

10.1056/NEJMc053610

10.1016/j.lungcan.2007.05.014

10.1093/annonc/mdj114

10.1111/j.1349-7006.2007.00600.x

10.1158/1078-0432.CCR-08-0332

10.1038/nrc2499

10.1126/science.1171837

10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D

10.1002/(SICI)1096-9896(199911)189:3<358::AID-PATH452>3.0.CO;2-1

10.1053/hupa.2003.8

Chung J. H., Rho J. K., Xu X., Lee J. S., Yoon H. I., Lee C. T., Choi Y. J., Kim H. R., Kim C. H., Lee J. C., Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer, 10.1016/j.lungcan.2010.11.011 (2010). PubMed

Uramoto H., Iwata T., Onitsuka T., Shimokawa H., Hanagiri T., Oyama T., Epithelial–mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 30, 2513–2517 (2010).

10.1016/j.ccr.2009.03.022

10.1016/j.ccr.2010.04.026

10.1016/j.cell.2010.02.027

10.1158/1078-0432.CCR-07-0560

Oxnard G. R., Arcila M. E., Sima C., Riely G. J., Chmielecki J., Kris M. G., Pao W., Ladanyi M., Miller V. A., Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res., 10.1158/1078-0432.CCR-10-2692 (2010). PubMed

10.1073/pnas.0803217105